Abstract library

25 results for "fibrosis".
#423 Case Report : A Rare Cause of Retroperitoneal Fibrosis Responding to Steroids
Introduction: Retroperitoneal fibrosis is a rare inflammatory disease. Neuroendocrine tumors are a heterogenous group that arise from enterochromaffin cells, most commonly in the gastrointestinal tract. Their capacity to secrete hormones, five HT, tachykinins etc, are responsible for symptoms known as carcinoid syndrome. However NETS, particularly arising from the midgut, can cause fibrosis. This can result in bowel obstruction, but also cause fibrosis in the retroperitoneum, lungs and cardiac valvular fibrosis.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Dalvinder Mandair
#1886 Effect of Treatment with Prolonged-Release Somatostatin Analogues on the Concentration of Serum Fibrosis Markers in Patients with Carcinoid Syndrome.
Introduction: A fibrosis is a major local and/or distant complication of neuroendocrine tumours (NETs) of the small intestine secreting serotonin. Tumour cells produce connective tissue growth factor CTGF and transforming growth factor TGFα and TGFβ which locally stimulate fibrosis and cause distant fibrosis.
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: MD Wanda Foltyn
#2999 Aberrant Tryptophan Metabolism in Stromal Cells Is Associated with Mesenteric Fibrosis in Small Intestinal Neuroendocrine Tumours
Introduction: Increased levels of serotonin secretion are associated with mesenteric fibrosis (MF) in small intestinal neuroendocrine tumors (SI-NETs). However, only a proportion of patients with increased serotonin production will develop mesenteric fibrosis.
Conference: 17th Annual ENETS Conference (2020)
Category: Basic Science - Genetics, epigenetics, miRNAs, Omics
Presenting Author: Drs. Anela Blazevic
#2288 Predicting Resectability of Primary Tumor and Mesenteric Lumps in Patients with Small Intestine Neuroendocrine Tumors
Introduction: Vascular infiltration and mesenteric fibrosis may jeopardize resection of primary tumor (PT) and mesenteric metastatic lumps (MLs) in small-intestine neuroendocrine tumors (SI-NETs).
Conference: 15th Annual ENETS conference (2018)
Category: Surgical treatment and Ablative Therapies
Presenting Author: MD Alessandra Nella Piccioli
#526 Association Between Activin A & NT-pro-BNP in Carcinoid Heart Disease and Intestinal Desmoplasia in Patients with Metastatic Midgut and Pelvic NET
Introduction: Carcinoid heart disease (CHD) involves cardiac valvular fibrosis and volume overload. N-terminal pro-brain natriuretic peptide (NT-pro-BNP) is released by the myocardium in response to increased wall stress in CHD. Activin A is a member of the TGF-ß superfamily involved in fibrogenesis.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Daniel Knight
Authors: Knight D, Khan M, Gobinathan S, Nair D, ...
#2995 Prediction of Symptomatic Mesenteric Mass in Patients with Small Intestinal Neuroendocrine Tumors Using a CT Radiomics Approach
Introduction: A mesenteric mass surrounded by fibrosis is a hallmark feature of small intestinal neuroendocrine tumors (SI-NETs) that can induce severe abdominal complications. To improve clinical outcome, there is a need for personalized treatment strategies based on accurate prediction of development of abdominal complications.
Conference: 17th Annual ENETS Conference (2020)
Category: Imaging and Interventions (radiology, endoscopy)
Presenting Author: Drs. Anela Blazevic
#356 Activin A in Carcinoid Heart Disease: A Possible Role in Diagnosis and Pathogenesis
Introduction: Carcinoid heart disease (CHD), a complication of NETs, is characterized by right heart fibrotic lesions. In addition to serotonin, cytokines and growth factors with fibrogenic properties may play a role.
Conference:
Category: Basic
Presenting Author: MD, PhD Deidi S. Bergestuen
#1272 Telotristat Etiprate Appears to Halt Carcinoid Heart Disease
Introduction: Carcinoid Heart Disease (CHD) is a serious complication of the Carcinoid Syndrome (in as many as 50% of patients during the course of their disease). 46% of cases operated with bioprosthetic valves develop recurrent carcinoid valvulopathy on the newly implanted tissue valves. Until now, only mechanical prosthetic valves avoid recurrent fibrosis.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Others
Presenting Author: MD, FACC, FCCP Jerome Zacks
Authors: Zacks J, Lavine R, Ratner L, Warner R, ...
#47 Plasma CCN2/connective tissue growth factor is associated with right ventricular dysfunction in Patients with Neuroendocrine Tumors
Introduction: Carcinoid heart disease (CHD) is a known complication of neuroendocrine tumors (NETs), particularly of those arising from the small intestine, appendix and proximal colon (previously known as mid-gut carcinoids). CHD is characterized by right heart fibrotic lesions and has traditionally been defined by the degree of valvular involvement, most commonly in the form of tricuspid regurgitation. Right ventricular (RV) dysfunction due to mural involvement may also be a manifestation. Connective tissue growth factor (CCN2) is upregulated in many fibrotic disorders. Increased tumor expression of CCN2 has been shown in patients with small intestinal NETs associated with peritoneal fibrosis. At present, its role in carcinoid heart disease is unknown.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr. Deidi S Bergestuen
#104 Myocardial motion abnormalities in patients with carcinoid disease without overt carcinoid heart disease
Introduction: Cardiac abnormalities occur in 15-70% of patients with carcinoid disease, typified by fibrosis of the right-sided valves. Myocardial motion abnormalities in subjects without overt carcinoid heart disease have not been previously described. Tissue Doppler Imaging (TDI) allows quantative analysis of myocardial motion. We used this technique to investigate whether myocardial motion is reduced, suggesting fibrosis, in patients with carcinoid disease.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Christopher Wong
Close
Notice

Dear conference participant,

Thank you for participating in the ENETS Virtual Conference 2020!

You now have the opportunity to view the webcasts, abstracts and e-posters via My ENETS. Don't miss on any of the exciting talks and take your time to view the clinical and basic science abstract sessions.

If you require a certificate of attendance, please log into My ENETS and select “Annual Conferences” from the side menu, then click on “My registrations” and select your registration for 2020. Please choose "Certificate o.A." to receive your certificate of attendance.

A note on CME accreditation:

ENETS has been liaising with UEMS regarding CME accreditation for the virtual conference. At present, we do not have a definitive answer. We will keep you updated.

 

Wishing you all the best,

The entire ENETS team